ArticleBMC microbiology2025
Resistance profile of Escherichia colis trains isolated at the main hospital in Dakar retrospective study over 10 years.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oral and plasma microbiome in the context of acute febrile illness.medRxiv : the preprint server for health sciences · 2026Article
- Supporting One Health policies to manage antibiotic resistance in Senegal: a systems analysis using group model building.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of this work is to describe the trends in antimicrobial resistance profiles of E. coli strains isolated from various clinical specimens at the main hospital in Dakar over a ten-year period. METHODOLOGY: This was a retrospective, cross-sectional descriptive and analytical study over 10 years 2012–2021] of all E. coli isolated at the HPD laboratory. Data were collected from the INLOG laboratory information system. The descriptive analysis of the data obtained was done with the software Excel (version 16.78.3, 23102801) and R (4.3.3).
resultsOf 23,311 bacterial species isolated, 7,797 E. coli (33.4%) were identified. The median age of patients was 52 (23–69), 1D; 100 years old] with a slight male predominance, sex ratio at 1.1. The resistance rates of E. coli to antibiotics were generally high: 85% with ampicillin, 46% with amoxicillin + clavulanic acid, 27% with cephalosporins of 3rd generation and 43% with pefloxacin. Between 2012 and 2021, a significant increase in E. coli resistance was observed (p < 0.005) for most antibiotics, except gentamicin, tobramycin, and cotrimoxazole, which showed a decreasing trend. Resistance rates increased from 28 to 41% for 3rd generation cephalosporins, 38 to 65% for amoxicillin + clavulanic acid and 51 to 56% for quinolones. Multidrug-resistant bacteria accounted for 28.47% (n = 2220) with a predominance of extended spectrum beta lactamases ESBL 24.34% (n = 1898).
conclusionThis study highlights a concerning resistance profile of Escherichia coli to commonly used antibiotics, particularly beta-lactams, fluoroquinolones, and aminoglycosides. Over time, a marked increase in multidrug-resistant (MDR) strains has also been observed, along with an alarming rise in carbapenem resistance. These findings underscore the urgent need to strengthen antibiotic stewardship policies, implement regular surveillance of resistance profiles, and reinforce infection prevention and control measures.Keywords: Escherichia coli, bacterial resistance, Dakar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.